CN119039069A - 一种抗衰硒肽肽精华营养液及其制备工艺 - Google Patents
一种抗衰硒肽肽精华营养液及其制备工艺 Download PDFInfo
- Publication number
- CN119039069A CN119039069A CN202410513555.XA CN202410513555A CN119039069A CN 119039069 A CN119039069 A CN 119039069A CN 202410513555 A CN202410513555 A CN 202410513555A CN 119039069 A CN119039069 A CN 119039069A
- Authority
- CN
- China
- Prior art keywords
- selenium
- peptide
- protein
- aging
- rich
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 41
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 98
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 91
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 86
- 239000011669 selenium Substances 0.000 claims abstract description 86
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 240000005528 Arctium lappa Species 0.000 claims abstract description 50
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 50
- 235000008078 Arctium minus Nutrition 0.000 claims abstract description 48
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 34
- 244000269722 Thea sinensis Species 0.000 claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 24
- 241000196324 Embryophyta Species 0.000 claims abstract description 21
- 241000252185 Cobitidae Species 0.000 claims abstract description 17
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims abstract description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 15
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 13
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 108010010803 Gelatin Proteins 0.000 claims abstract description 7
- 240000004658 Medicago sativa Species 0.000 claims abstract description 7
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920000159 gelatin Polymers 0.000 claims abstract description 7
- 239000008273 gelatin Substances 0.000 claims abstract description 7
- 235000019322 gelatine Nutrition 0.000 claims abstract description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 5
- 229920001503 Glucan Polymers 0.000 claims abstract description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 5
- 241000411851 herbal medicine Species 0.000 claims abstract description 5
- 239000000600 sorbitol Substances 0.000 claims abstract description 5
- 235000008939 whole milk Nutrition 0.000 claims abstract description 5
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 241000345998 Calamus manan Species 0.000 claims abstract 2
- 235000012950 rattan cane Nutrition 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 72
- 239000000243 solution Substances 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 20
- 229940088594 vitamin Drugs 0.000 claims description 15
- 229930003231 vitamin Natural products 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000016709 nutrition Nutrition 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 claims description 5
- 230000035764 nutrition Effects 0.000 claims description 5
- 235000019640 taste Nutrition 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 3
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 3
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000010413 mother solution Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 240000002791 Brassica napus Species 0.000 claims 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims 1
- 238000010668 complexation reaction Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000007071 enzymatic hydrolysis Effects 0.000 claims 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims 1
- 230000002262 irrigation Effects 0.000 claims 1
- 238000003973 irrigation Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 22
- 230000036039 immunity Effects 0.000 abstract description 15
- 230000001093 anti-cancer Effects 0.000 abstract description 14
- 235000012000 cholesterol Nutrition 0.000 abstract description 11
- -1 lipid peroxides Chemical class 0.000 abstract description 11
- 239000003053 toxin Substances 0.000 abstract description 10
- 231100000765 toxin Toxicity 0.000 abstract description 10
- 108700012359 toxins Proteins 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 8
- 206010011224 Cough Diseases 0.000 abstract description 7
- 230000035876 healing Effects 0.000 abstract description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 208000007536 Thrombosis Diseases 0.000 abstract description 5
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 5
- 208000006673 asthma Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 210000000981 epithelium Anatomy 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 230000001850 reproductive effect Effects 0.000 abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 230000004199 lung function Effects 0.000 abstract description 3
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 230000007998 vessel formation Effects 0.000 abstract 1
- 229940091258 selenium supplement Drugs 0.000 description 59
- 241000229143 Hippophae Species 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 230000001737 promoting effect Effects 0.000 description 18
- 235000013616 tea Nutrition 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 230000003405 preventing effect Effects 0.000 description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 15
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 14
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 235000001465 calcium Nutrition 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 9
- 235000003935 Hippophae Nutrition 0.000 description 9
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 229930003944 flavone Natural products 0.000 description 9
- 150000002212 flavone derivatives Chemical class 0.000 description 9
- 235000011949 flavones Nutrition 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 9
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 8
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 description 8
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 description 8
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 description 8
- 241000219823 Medicago Species 0.000 description 8
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 8
- 235000009569 green tea Nutrition 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 description 8
- 206010010774 Constipation Diseases 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 7
- 235000005487 catechin Nutrition 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000000711 cancerogenic effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 230000005747 tumor angiogenesis Effects 0.000 description 6
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 6
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 229920001202 Inulin Polymers 0.000 description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 5
- 150000001746 carotenes Chemical class 0.000 description 5
- 235000005473 carotenes Nutrition 0.000 description 5
- 229950001002 cianidanol Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940030275 epigallocatechin gallate Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 5
- 229940029339 inulin Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- PJLHTVIBELQURV-UHFFFAOYSA-N 1-pentadecene Chemical compound CCCCCCCCCCCCCC=C PJLHTVIBELQURV-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 3
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 3
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 3
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 3
- WKSUCCVMYJRMFR-UHFFFAOYSA-N Dehydrocostus lactone Natural products C12OC(=O)C(=C)C2CCC(=C)C2(C)C1(C)C(=C)CC2 WKSUCCVMYJRMFR-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 3
- ZEAXBOPUTILUGH-UHFFFAOYSA-N aphyllocladine Natural products S1C(C#CC)=CC=C1C1=CC=C(C=O)S1 ZEAXBOPUTILUGH-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 3
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 229940117948 caryophyllene Drugs 0.000 description 3
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- NETSQGRTUNRXEO-XUXIUFHCSA-N dehydrocostus lactone Chemical compound C([C@H]1C(=C)C(=O)O[C@@H]11)CC(=C)[C@H]2[C@@H]1C(=C)CC2 NETSQGRTUNRXEO-XUXIUFHCSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000021332 multicellular organism growth Effects 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 235000015500 sitosterol Nutrition 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- CHXZRHMQQRUVHF-UHFFFAOYSA-N 2-hex-5-en-1,3-diynyl-5-prop-1-ynylthiophene Chemical compound CC#CC1=CC=C(C#CC#CC=C)S1 CHXZRHMQQRUVHF-UHFFFAOYSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- SJVJMFXCINSXFF-UHFFFAOYSA-N 5-(5-prop-1-ynylthiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C#CC)=CC=C1C1=CC=C(C(O)=O)S1 SJVJMFXCINSXFF-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 240000001592 Amaranthus caudatus Species 0.000 description 2
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241001018563 Nekemias grossedentata Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 241000269799 Perca fluviatilis Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004178 amaranth Substances 0.000 description 2
- 235000012735 amaranth Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 150000001765 catechin Chemical class 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 2
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000001543 purgative effect Effects 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 229940065287 selenium compound Drugs 0.000 description 2
- 150000003343 selenium compounds Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ANIAOEHACLPLEY-UHFFFAOYSA-N thiophene B Natural products CC#CC#CC1=CC=C(C#CC=C)S1 ANIAOEHACLPLEY-UHFFFAOYSA-N 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- RVVLUQPXASICPK-UHFFFAOYSA-N 1-[5-(5-prop-1-ynylthiophen-2-yl)thiophen-2-yl]ethane-1,2-diol Chemical compound S1C(C#CC)=CC=C1C1=CC=C(C(O)CO)S1 RVVLUQPXASICPK-UHFFFAOYSA-N 0.000 description 1
- UPOWHCBUDJLAIB-UHFFFAOYSA-N 1-[5-(5-prop-1-ynylthiophen-2-yl)thiophen-2-yl]ethanone Chemical compound S1C(C#CC)=CC=C1C1=CC=C(C(C)=O)S1 UPOWHCBUDJLAIB-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-BYPYZUCNSA-N 2-Methylbutanoic acid Natural products CC[C@H](C)C(O)=O WLAMNBDJUVNPJU-BYPYZUCNSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- UJADCNYXDHHISU-UHFFFAOYSA-N 3-methyl-6,9-dimethylidene-3a,4,5,6a,7,8,9a,9b-octahydro-3h-azuleno[4,5-b]furan-2-one Chemical compound C1CC(=C)C2CCC(=C)C2C2OC(=O)C(C)C21 UJADCNYXDHHISU-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000208843 Arctium Species 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 229930020125 aflatoxin-B1 Natural products 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001518 anti-nephritic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- PJWPOUFMMWFJOL-UHFFFAOYSA-N beta-sitosterol-beta-D-glucoside Natural products CCC(CCC(C)C1CCC2C3C=CC4CC(CCC4(C)C3CCC12C)OC5OC(CO)C(O)C(O)C5O)C(C)C PJWPOUFMMWFJOL-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000010336 energy treatment Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- VKQRFUTZCXPPPY-UHFFFAOYSA-N heptadec-1-ene Chemical compound C=CCCCCCCCCCCCCCCC.C=CCCCCCCCCCCCCCCC VKQRFUTZCXPPPY-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical group C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- WKQBNYGTPIGLMV-UHFFFAOYSA-N lappaphen-a Natural products CC#Cc1ccc(s1)c2ccc(s2)C(=O)CC3(O)C4CCC(=C)C5CCC(=C)C5C4OC3=O WKQBNYGTPIGLMV-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- KKBHBCOJHHCOCL-UHFFFAOYSA-N tridec-1-ene-3,5,7,9,11-pentayne Chemical compound CC#CC#CC#CC#CC#CC=C KKBHBCOJHHCOCL-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C05—FERTILISERS; MANUFACTURE THEREOF
- C05C—NITROGENOUS FERTILISERS
- C05C11/00—Other nitrogenous fertilisers
-
- C—CHEMISTRY; METALLURGY
- C05—FERTILISERS; MANUFACTURE THEREOF
- C05G—MIXTURES OF FERTILISERS COVERED INDIVIDUALLY BY DIFFERENT SUBCLASSES OF CLASS C05; MIXTURES OF ONE OR MORE FERTILISERS WITH MATERIALS NOT HAVING A SPECIFIC FERTILISING ACTIVITY, e.g. PESTICIDES, SOIL-CONDITIONERS, WETTING AGENTS; FERTILISERS CHARACTERISED BY THEIR FORM
- C05G3/00—Mixtures of one or more fertilisers with additives not having a specially fertilising activity
-
- C—CHEMISTRY; METALLURGY
- C05—FERTILISERS; MANUFACTURE THEREOF
- C05G—MIXTURES OF FERTILISERS COVERED INDIVIDUALLY BY DIFFERENT SUBCLASSES OF CLASS C05; MIXTURES OF ONE OR MORE FERTILISERS WITH MATERIALS NOT HAVING A SPECIFIC FERTILISING ACTIVITY, e.g. PESTICIDES, SOIL-CONDITIONERS, WETTING AGENTS; FERTILISERS CHARACTERISED BY THEIR FORM
- C05G5/00—Fertilisers characterised by their form
- C05G5/20—Liquid fertilisers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明的防癌抗衰硒肽肽精华液营养液公开由富硒植物、富含蛋白肽动物、特效中草药组成的一种抗衰硒肽肽精华液新型配方,各组份的配比为:植物硒粉6mg、泥鳅ACE蛋白肽30mg、蛋白清肽50‑60mg、阿胶肽30‑50mg、沙棘果粉40‑60mg、表没食子儿茶素及酸酯40mg、柠檬酸20‑40mg、酵母葡聚糖50mg、山梨糖醇180mg、全脂乳粉80‑100mg、牛蒡根100mg、苜蓿30‑50mg、富硒藤茶精华液30mg;本发明帮助人体清除自由基、排除体内毒素、抗氧化、能有效的抑制过氧化脂质的产生,防止血凝块,清除胆固醇,阻断肿瘤血管形成、抗癌抗衰、养护心脑血管、增强生殖功能、补肾益气滋补壮阳、益肝利胆、止咳祛痰平喘改善肺功能、促进组织再生和上皮组织愈合、润肤养颜、增强人体免疫力等作用。
Description
技术领域
本发明涉及涉及抗衰技术领域,具体为一种抗衰硒肽肽精华营养液及其制备工艺。
背景技术
硒能增强动物和人的体液及细胞免疫功能,增强T细胞介导的肿瘤特异性免疫,并有利于细胞毒性T淋巴细胞的诱导并加强它的活性;硒制剂还能显著提高巨噬细胞吞噬率和放、化疗病人血清IgG、IgA含量,这些结果证实硒制剂是一种有效的免疫调节剂。
目前市场上的硒肽肽精华营养液成分配比单一,人体对硒的吸收能力弱,硒对于人体的功效显示弱,基于硒对人体的作用,发明一种促进人体更好吸收精华营养液;
此发明的一种防癌抗衰精华液特别适合癌症晚期、危重病人、小孩、老人等对固体药片吞咽困难者吸吮服用、同时更利于吸收。
发明内容
针对现有技术的不足,本发明提供了一种抗衰硒肽肽精华营养液。
为实现以上目的,本发明通过以下技术方案予以实现:一种抗衰硒肽肽精华营养液由富硒植物、富含蛋白肽动物、特效中草药有效成分提取组成的一种抗衰硒肽肽精华液新型配方;
各组份的配比为:
植物硒粉6mg、泥鳅ACE蛋白肽30mg、蛋白清肽50-60mg、阿胶肽30-50mg、沙棘果粉40-60mg、表没食子儿茶素及酸酯40mg、柠檬酸20-40mg、酵母葡聚糖50mg、山梨糖醇180mg、全脂乳粉80-100mg、牛蒡根100mg、苜蓿30-50mg、富硒藤茶精华液30mg。
优选的,所述植物栖粉为西兰花富硒蛋白粉1mg、麦苗富硒蛋白粉1mg、油菜富硒蛋白粉3mg混合而成;
优选的,所述蛋白肽为泥鳅ACE蛋白肽30mg、蛋白清肽50mg、阿胶肽30mg混合而成;
优选的所述苜蓿50mg优选河北等地优质的苜蓿为原料,采用严格的生产工艺,口感鲜美,营养丰富尤其是富含蛋白质和维生素;
优选的,所述沙棘果粉40mg混合而成;
优选的,所述表没食子儿茶素及酸酯40mg混合而成;
优选的,所述牛蒡根100mg混合而成;
优选的,所述富硒藤茶精华液30mg混合而成。
本发明公开了一种抗衰硒肽肽精华营养液,其具备的有益效果如下:
该抗衰硒肽肽精华营养液,防癌抗衰硒肽肽精华液营养液可以帮助人体清除自由基、排除体内毒素、抗氧化、能有效的抑制过氧化脂质的产生,防止血凝块,清除胆固醇,阻断肿瘤血管形成、抗癌抗衰、养护心脑血管、增强生殖功能、补肾益气滋补壮阳、益肝利胆、止咳祛痰平喘改善肺功能、促进组织再生和上皮组织愈合、润肤养颜、增强人体免疫力等作用。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明实施例公开一种抗衰硒肽肽精华营养液;
实施例一:
本发明实施例中,一种防癌抗衰营养营养液,各组份的重量配比为:
植物硒粉6mg、泥鳅ACE蛋白肽30mg、蛋白清肽50-60mg、阿胶肽30-50mg、沙棘果粉40-60mg、表没食子儿茶素及酸酯40mg、柠檬酸20-40mg、酵母葡聚糖50mg、山梨糖醇180mg、全脂乳粉80-100mg、牛蒡根100mg、苜蓿30-50mg、富硒藤茶精华液30mg。
实施例二:
本发明实施例中,一种防癌抗衰营养营养液,各组份的重量配比为
植物硒粉6mg、泥鳅ACE蛋白肽30mg、蛋白清肽50-60mg、阿胶肽30-50mg、沙棘果粉40-60mg、表没食子儿茶素及酸酯40mg、柠檬酸20-40mg、酵母葡聚糖50mg、山梨糖醇180mg、全脂乳粉80-100mg、牛蒡根100mg、苜蓿30-50mg、富硒藤茶精华液30mg。
所述植物栖粉为西兰花富硒蛋白粉1mg、麦苗富硒蛋白粉1mg、油菜富硒蛋白粉4mg混合而成。
本发明实施例中,一种防癌抗衰精华液按各组份的重量配比将原料进行配料、混合后制成成品。
主要成分功效简述
硒的功效:
一、硒有抗癌作用:硒能够调节维生素A、维生素C、维生素E、维生素K的吸收与利用,可以预防近视、白内障、视网膜病、眼底疾病、老年黄斑变性等疾病;硒能保护神经细胞免受氧化损害,预防神经性疾病等;硒对修复脏器损伤、抗击衰老作用确切、显著,能强效祛除高血压、糖尿病、动脉硬化、脑中风、冠心病、肿瘤、肾虚前列腺、失眠、皮肤病等,增强免疫功能预防肿瘤。具有很好的抗氧化作用,帮助人体清除自由基,延缓人体的衰老。
二、硒具有抗氧化作用:硒是谷胱甘肽过氧化物酶(GSH-Px)的组成成分,每摩尔的GSH-Px中含4克原子硒,此酶的作用是催化还原性谷胱甘肽(GSH)与过氧化物的氧化还原反应,所以可发挥抗氧化作用,是重要的自由基清除剂。在体内,GSH-Px与维生素(维生素食品)E抗氧化的机制不同,两者可以互相补充,具有协同作用。
三、增强免疫力:有机硒能清除体内自由基,排除体内毒素、抗氧化、能有效的抑制过氧化脂质的产生,防止血凝块,清除胆固醇,增强人体免疫功能。
四、防止糖尿病(糖尿病食品):硒是构成谷胱甘肽过氧化物酶的活性成分,它能防止胰岛β细胞氧化破坏,使其功能正常,促进糖份代谢、降低血糖和尿糖,改善糖尿病患者的症状。
五、防止白内障:硒可保护视网膜,增强玻璃体的光洁度,提高视力,改善近视、有防止白内障的作用。
六、防止心脑血管疾病:硒是维持心脏正常功能的重要元素,对心脏肌体有保护和修复的作用。人体血硒水平的降低,会导致体内清除自由基的功能减退,造成有害物质沉积增多,血压升高、血管壁变厚、血管弹性降低、血流速度变慢,送氧功能下降,从而诱发心脑血管疾病的发病率升高,然而科学补硒对预防心脑血管疾病、高血压、动脉硬化等都有较好的作用。
七、阻断肿瘤血管形成:防止肿瘤复发、转移;硒能抑制肿瘤血管形成,预防肿瘤生长,转移。肿瘤转移和生长,依赖于自身建立生血管生成抑制因子”有促进作用,营造抗“肿瘤新生血管”形成的环境,从而抑制“肿瘤新生血管网”的形成与发展,切断肿瘤细胞的营养供应渠道。由于肿瘤得不到营养来源,会逐渐枯萎、消亡;同时由于切断了肿瘤的代谢渠道,肿瘤组织自身废物不能排出,肿瘤逐渐变性坏死。
八、提高免疫力:研究表明,硒显著地影响免疫系统所包含的全部三种调节机制,即细胞免疫、体液免疫和非特异免疫。硒还能促进淋巴细胞产生抗体,使血液免疫球蛋白水平增高或维持正常,因此临床中给肿瘤患者适量补硒,可有效提高患者机体免疫功能,维护心、肝、肺、胃等重要器官正常功能的作用,有助于预防老年性心、脑血管等功能的衰退。
九.硒能抗氧化抗衰老、紧致肌肤、淡斑、美白保护、修复受损皮肤细胞,提高红细胞的携氧能力润泽肌肤;这样其携氧能力增强,把充足的氧带给机体的每一个细胞。这样,皮肤细胞的代谢水平才能更加平稳,肌肤更加水润、光滑;
十.硒能够增强生殖功能,克服射精受阻,提升精子活力、提高受孕胎率减少发生畸形,治疗子宫炎等等症状。
硒的抗癌作用与提高免疫功能和清除自由基三者的有效结合可以延缓衰老。
肽是分子结构介于氨基酸和蛋白质之间的一类化合,由2个或2个以上氨基酸分子通过肽键相互连接而成,是蛋白质的结构与功能片段,并使蛋白质具有数以千万计的生理功能,其本身也具有很强的生物活性,氨基酸作为肽的基本构成单位,其种类、数目与排列顺序的不同决定了肽纷繁复杂的结构与功能。
由2个或3个氨基酸脱水缩合而成的肽分别称为二肽或三肽,以此类推为四肽、五肽等,肽和蛋白质之间没有严格的区分,一般认为,以氨基酸数量来划分,肽链上氨基酸数目在10个以内的为寡肽,10~15个的为多肽,50个以上的则为蛋白质,人们习惯上也把寡肽称之为短肽或低聚肽,其中的二、三肽又称为小肽。
一、肽在人体起活性作用:人体内的活性物质主要是以肽的形式存在的,人体如果没有肽,也就没有活性,人体如果有足够肽,生命才能旺盛、健康,
二、肽在人体起着激素的作用:肽在人体起着多种激素的作用,它是人体多种激素的底物,也是多种激素的来源和源泉。
三、肽在人体生长发育过程中起着重要作用:人体的生长发育和许多因素有关,特别是人体蛋白质,人体蛋白质又是以肽的形式存在的,人体生长发育的物质基础是肽;人体生长发育离不开激素,而激素也是肽的一种表现形式,因此,人体生长发育无论从哪方面讲,都离不开肽,肽在人体的生长发育中起着重要作用。
四、肽在人体起着神经递质的作用:人体活着的神经,也是以肽的形式存在,肽在人体起着神经递质作用,它可以传递信息,使人体更敏捷,更灵通,使人体各部位、各器官配合更一致,使人体的生命活动更协调、更一致、更成功,人体如果缺乏肽,神经缺乏活性,生命活动就反应出迟钝、麻痹;
五、肽在人体起着载体的作用:肽在人体的载体作用,主要表现在,它可将人体平常所食的各种营养物质,如钙、铁、锌、锰、硒等常量元素和微量元素载在自己的本体上,输送到人体所需部位,发挥各种不同的生理活性作用,以满足人体所需的营养物质,钙类等常量元素和铁、锌、锰、硒等各种微量元素,需与肽结合,否则就不能被人体吸收,会产生就地沉淀,而被排出体外,因此,补钙不补肽,就等于白补钙。
六、肽在人体起着运输工具的作用:肽在人体作为运输工具,将外界进入人体、人体已存在的各种营养物质运输到人体所需的部位,使人体所需的各种营养物质通过肽的运输,顺利的到达人体所需部位,以满足人体营养准时需求。
七、肽在人体起调节作用:肽进入人体以后能合成细胞,同时也能调节细胞的功能活动,还可以通过DNA转录,影响特异的蛋白合成。
八、肽在人体起免疫调节作用:当肽进入人体循环系统和组织后,不需消化,高效吸收,促进蛋白质合成,可刺激机体的免疫系统发生特异性免疫应答反应,起到调节免疫的作用。
九、肽在人体起动力作用:小肽在被人体吸收时不需耗费人体的能量,而其他物质的吸收是要耗费人体能量的,小肽是以自己的动力促使人体吸收,小肽对其他营养物质起载体和运输作用时,也都是以自己的动力作用将它们运输和输送到人体所需部位,小肽在人体的动力作用是显而易见的。
泥鳅蛋白肽的功效与作用
以泥鳅蛋白酶解物中提取的ACE抑制肽为原料。
泥鳅ACE抑制肽在较宽的pH值(3~9)范围内具有优良的溶解性能,氮溶解指数均在70%以上,泥鳅ACE抑制肽具有较好的乳化能力(60.8%)和乳化稳定性(68.6%),泥鳅蛋白水解后,ACE抑制肽的起泡性及起泡稳定性分别降低15.8%和15.5%,通过氨基酸组成分析,泥鳅ACE抑制肽的氨基酸组成平衡性好,必需氨基酸总含量达到42.52%,功效比值PERⅠ为2.9,PERⅡ为2.9,PERⅢ为2.3,高含量的疏水性氨基酸(47.9%)、芳香族氨基酸(13.3%)以及支链氨基酸(17.7%),是泥鳅ACE抑制肽具有降压特性的重要物质来源。
泥鳅的含铁量很高,可以促进体内血红蛋白的合成,有补血的功效。泥鳅属于低脂肪、低胆固醇食物,还含有不饱和脂肪酸、能有效预防动脉硬化、可以消退黄疸及降低转氨酶,可以治疗急性肝炎,并可以显效地恢复肝功能。
泥鳅含有多种的蛋白质,可以促进人体的蛋白质合成,有增加的体力和免疫力作用,泥鳅还含有微量元素磷和钙有强筋健骨的功能、能滋阴止渴、清热祛湿,可以治疗黄疸、小便不利等。
苜蓿的功效与作用
1.为消炎止血。
苜蓿富含维生素K,这种维生素主要起到止血的作用,同时也有辅助治疗炎症的作用。中医常用苜蓿来治疗鼻出血、大便出血、胃出血、肠道出血等。还可用于治疗关节炎等慢性炎症。
2.通经。
这类中药材还具有通经活络的功效,可以促进血液循环,缓解肌肉紧张。那些患有腰肌劳损或肌肉受损疾病的人可以多吃一些,这样不仅能减轻疼痛,还能使病情迅速恢复。
3.凉血败火。
苜蓿属于凉性中草药,这种中草药能促进热毒排出,缓解虚火。由于血热导致的胃痛或头痛等症状,吃苜蓿也能缓解症状。
5.增强体质。
蛋白质、胡萝卜素、钙元素、铁元素、碳水化合物等营养元素都是苜蓿的主要成分。添加这些营养成分还能增强体质,提高免疫力。
食子儿茶素及酸酯(简称EGCG)
EGCG是从中国绿茶中提取的一种成份,它是绿茶主要的活性和水溶性成份,是儿茶素中含量*的组分,占绿茶毛重的9%-13%,因为具有特殊的立体化学结构,EGCG具有非常强的抗氧化活性,抗氧化活性至少是维生素C的100多倍,是维生素E的25倍,能够保护细胞和DNA受损害。
食子儿茶素及酸酯(简称EGCG)在抗癌和心血管疾病方面担当了重要的角色,此外,它也用作肿瘤多药耐药性的逆转剂,能够改善癌细胞对化疗的敏感性并减轻对心脏的毒性。
EGCG是绿茶茶多酚的主要组成成分,也是绿茶儿茶素类的主成分,儿茶素类包括EGCG、EGC、ECG、EC、GCG等,其中抗氧化活性依次为EC许多研究表明EGCG具有抗自由基DNA损害,抗辐射和紫外线,阻止油脂过氧化,减少血清中低密度胆固醇、超低密度胆固醇和甘油三酯的含量,干扰癌细胞生存所需的信号传递,抑制饮食中的致癌物质,与肠、肝、和肺中的其他酶和抗氧化剂作用共同阻止某些致癌物质的活力,清除自由基,抵御污染、日晒和吸烟的影响,防治皮肤老化和起皱。
绿茶儿茶素EGCg对病毒有灭活作用。但它又具有很强的抗氧化作用,极易氧化变质,缺乏储存稳定性。新配方克服了这一问题,在水中可保持高浓度,并通过与病毒蛋白结合,防止病毒进入细胞,以对抗各种反复变异的病毒。新配方可稳定在10,000ppm的高浓度,而且浓度可以很容易地通过稀释来调整。所有成分都是可食用的食品添加剂,各年龄段均可服用,用于口腔护理。
此外,由于儿茶素EGCg特有的涩味、苦味或抗褪色功能,几乎不会对现有产品的原味、香气或颜色造成损害,该产品可用于各种领域。又因其对细菌及病毒非常有效,该产品还可用作厨房和食品处理中酒精类手部消毒剂的替代品,以及用来预防人流感、禽流感和猪流感。
该成分对四种甲型和乙型流感病毒株的病毒颗粒吸附到或进入细胞的过程具有抑制作用。使用MDCK(马丁-达比犬肾)细胞进行的体外空斑减数实验证明,绿茶儿茶素表没食子儿茶素没食子酸酯(EGCg)在病毒复制过程中,通过抑制表没食子儿茶素没食子酸酯对细胞的吸附而具有抗病毒作用。
沙棘果
沙棘果的营养价值很高,含有脂肪、蛋白质、糖类、盐类和维生素,并且含量极其丰富。
每100g沙棘果汁中含维生素C500mg-400mg、维生素E250mg-400mg、维生素B1含0.05mg-0.3mg、维生素B2含0.03,g-0.15,g、维生素B12含0.2mg-0.88mg、维生素K族化合物115、P族维生素20mg-350mg。
1、对心血管疾病的防治作用;
沙棘果与沙棘叶中提取的总黄酮(TFH),是含有7种黄酮的一组化合物,其中含量较高的为异鼠李素及槲皮素。沙棘总黄酮可使心绞痛缓解,心功能及缺血性心电图好转,这与TFH具有增加冠状动脉血流量、增加心肌营养血流量、降低心肌耗氧量、抑制血小板聚集等作用有关。经国内、国际专家研究证实,沙棘总黄酮对心脏功能有加强作用,可以使心肌收缩能力增强,心肌舒张功能得到改善,对垂体后叶引起的心肌缺血有明显的对抗作用。对冠状动脉阻塞引起的心肌梗塞的面积能明显缩小,也能提高在常压和低压下的耐缺氧能力。
2、沙棘的抗癌作用;
沙棘果的抗癌作用除去其通过免疫机制或其他途径所引起的作用外,还有直接地抑制癌细胞作用以及阻断致癌因素的作用。沙棘汁经稀释成宜饮用的浓度后,能阻断N-亚硝基的合成,另外沙棘汁对致癌物N-二甲基亚硝胺(NDMA)也有阻断与防护的作用*沙棘黄酮中含有香豆素、异香豆素、呋喃香豆素、苦木素以及多酚类、5-羟色胺等具有综合抗癌作用的成分。实验证明沙棘提取物对肉瘤、淋巴细胞,白血病等具有明显的治愈效果和防治功能,此外,其对人类白血病细胞株(K562)及人类胃癌细胞株7901均有直接的杀伤作用。同时也发现沙棘提取物有阻断N-亚硝基化合物的致癌作用以及抑制黄曲霉素B1诱发癌前病灶的作用。通过其作用机理研究表明,沙棘提取物有增强人体免疫功能和激活巨噬细胞的吞噬作用,而且能增强氧自由基清除剂--超氧化物歧化酶的活性。
3、沙棘对肝病的防治作用
通过低温萃取技术从沙棘籽中萃取出的沙棘籽油是一种具有非常好的保肝、护肝保健功效的食用油脂。沙棘籽油对四氯化碳、乙醇、扑热息痛所致的肝损伤的谷丙转氨酶和谷草转氨酶的升高均有明显的抑制作用,并能对抗肝MDA(丙二醛)含量升高。其机理是沙棘籽油对抗了CCl3(三氯化碳)自由基的攻击,保护肝细胞膜。籽油对乙醇、扑热息痛所致的肝损伤均有明显的保护作用。
4、沙棘对胃病的防治作用
现代医学研究发现,沙棘籽油对醋酸法和慢性利血平法所致胃溃疡有良好的促进愈合作用,沙棘籽油中的β-谷甾醇-β-D-葡萄糖甙为抗胃溃疡的有效成分,能有效地保护胃粘膜及抑制胃酸分泌,使胃粘膜受损程度降低,沙棘籽油还有抗炎生肌、促进组织再生、促进溃疡愈合的作用。
5、沙棘对烧伤、烫伤等疗效
沙棘油具有神奇的促进组织再生和上皮组织愈合的作用,临床上和民间用于治疗烫伤、烧伤、刀伤和冻伤均取得极好的效果。不仅可以治疗轻度的烧伤、烫伤,也可治疗II、III度烧伤,每日在烧伤面涂敷2-3次,即可获得满意的效果,而且一般不留疤痕,对于化学烧伤同样有效,沙棘籽油治疗烧伤、烫伤等皮肤损伤其效果也非常不错。
6、沙棘的护肤养肤作用
沙棘籽油中的游离脂肪酸、碳氢化合物、甾醇总含量、磷脂、VE、VA、类胡萝卜素等这些护肤的主要成分的含量很高,比其它植物高出几倍,乃至几十倍。这些物质极易被皮肤吸收,具有近似于皮脂的护肤作用。沙棘籽油中的皮脂成分与其中的维生素E、A、维生素原浑然一体,营养全面,效果显著。
7、它有止咳祛痰平喘的作用,因此对于各种原因导致的急性支气管炎,肺炎导致的咳嗽痰多,可以用沙棘改善冠状动脉粥样硬化、改善高血压的危害。
8、它有消食化滞的作用,因此对于消化不良、食积,从而导致的腹痛,它有一定的作用。
9、它有活血散淤的作用,因此对于外伤引起的跌打损伤,导致的淤肿,或者是由于内脏疾病,脏腑疾病导致的淤血,特别是妇科引起的经闭血淤,有活血散淤的作用。
10、现代的药理学研究认为,沙棘果和沙棘油,具有很高的药用价值,它可以降低胆固醇,防止心绞痛,改善冠状动脉粥样硬化改善高血压的危害。
11、它对妇女的宫颈糜烂,也有很好的治疗效果。
12、沙棘的抗衰老作用、沙棘果的有效成分超氧化物歧化酶(SOD)具有清除人体内自由基的作用,同时又能增强免疫系统功能,调节免疫活性细胞,是一种有效的免疫调节剂,这对于提高人体的抗病能力,延缓人体的衰老,会有极其显著的作用。因此沙棘的作用比较广泛。
牛蒡根的功效与作用
牛蒡(Arctiumlappa L.)是菊科牛蒡属二年生草本植物。牛蒡茎叶含挥发油、鞣质、粘液质、咖啡酸等,果实含牛蒡甙、脂肪油等多种化学成分,牛蒡根具独特的芳香。《名医别录》记载牛蒡果实具有疏散风热,宣肺透疹,散结解毒之功效;根具有清热解毒,疏风利咽、散风热、消肿毒等功效,还有促进生长发育、抗细菌、抗真菌等作用。
中医学认为,牛蒡根味苦,药性寒;归肺经。具有疏散风热、宣肺透疹、解毒利咽的功效,可治疗风热感冒、头痛,咳嗽,热毒面肿,咽喉肿痛,齿龈肿痛,风湿痹痛,癥瘕积块,痈疖恶疮,痔疮脱肛等。疏风散热、解毒消肿,用于咳嗽、咽喉肿痛、便秘、风火上扰之头晕、耳鸣耳聋、目昏,外用治头面风毒赤肿、痔疮、风湿痹痛,肢节拘挛等。
现代药理学研究发现,牛蒡根含有牛蒡种噻吩-A和B、牛蒡苷元、牛蒡素B、牛蒡醇A和F、牛蒡酮A和B、牛蒡醇A和B、牛蒡醛、牛蒡酸B和C、牛蒡酸B甲酯、牛蒡酮A乙酸酯、去氢木香内酯、去氢二氢木香内酯、苯甲酸、丁香烯、槲皮素、咖啡酸、绿原酸、蒲公英甾醇、谷甾醇等成分。具有促进生长发育、抗真菌等作用。
牛蒡又名大力子、黑萝卜、万把钩、东洋人参,牛菜,为菊科二年生草本植物。每100克牛蒡中含有蛋白质4.7。
克,脂肪0.8克,糖3克,能量160千焦(38千卡),粗纤维2.4克,钙242毫克,磷61毫克,铁7.6毫克,胡萝卜素3.9毫克,维生素C25毫克。牛蒡可用来防治头痛、烦闷、金疮、皮肤、搔痒等症。牛蒡中可分离出一种广效的抗癌物质牛蒡酚,牛蒡的热水提取物也显示了较强的抗癌活性,预防癌症及动脉硬化,改善便秘,它的水溶纤维和不溶性纤维各占一半,可以使乳酸菌更活泼,彻底发挥改善便秘的功效,木质素是牛蒡所含的最多植物纤维的一种,它具有十分优异的抗菌作用。
中国《现代中药学大辞典》中,把牛蒡解释为它具有可促进生长,抑制肿瘤,抵抗菌类和真菌的植物,其胡萝卜素含量是胡萝卜的110倍,蛋白质和钙及植物纤维的含量等为根茎菜类蔬菜中之首。植物纤维有助于体内垃圾的清除,牛蒡中含有预防癌症消除致癌物质的成份。此外,牛蒡还有降压作用,对高血脂,糖尿病,风湿病,性功能低下,肥胖等有较好的改善作用。
化学分析
含愈创木内酯类化合物:牛蒡种噻吩-α(lap-paphen-a),牛蒡种噻-b(lappaphen-b)。又含硫炔类化合物,牛蒡酮(arctinone)a、b,牛蒡醇(arctinol)a、b,牛蒡醛(arctinal)、牛蒡酸(arcticacid)b、c,牛蒡酸b甲酯(methylarctateb)-1,11-十三碳二烯-3,5,7,9-四炔[(11E)-1,11-tridecadien-3,5,7,9-tetrayne],(3E,11E)-1,3,11-十三碳三烯-5,7,9-三炔[(3E,11E)-1,3,11-tridecatrien-5,7,9-triyen],(3E)-3-十三碳烯-5,7,9,11-四炔-1,2-环氧化合物[(3E)-3-tridecen-5,7,9,11-tetrayne-1,2-epoxide],(4E、6E、12E)-4,6,12-十四碳-8,10-二炔-1,3-二乙酸酯[(4E、6E、12E)-4,6,12-tetradecatrie]-8,10-二炔-1,3-二炔-1,3-二乙酸酯[(4E,6E)]-4,6-tetradecadien-8,10,12-triyn-1,3-diyldiac-etate],(4E,6Z)-4,6-十四碳二烯-8,10,12-三炔-1,3-二乙酸酯[(8Z,15Z)-十七碳-1,8,15-三烯-11,13-二炔[(8Z,15Z)-heptadeca-1,8,15-trien-11,13-diyn][3]。(S)-12,13-环氧-2,4,6,8,10-十三碳烯-3,5,7,9,11-五炔(1-tridecen-3,5,7,9,11-pentayne)。根中的挥发性成分有:去氢木香内酯(de-hydrocostuslactone),去氢二氢木香内酯(dehydrodihydrocostuslactone),3-辛烯酸(3-octenoicacid),3-已烯酸(3-hexenoicacid),2-甲基丙酸(2-methypropionicacid),2-甲基丁酸(2-methylbu-tyricacid),2-甲氧基-3-甲基吡嗪(2-methoxy-3-methylpyrazine),苯乙醛(phenyacetaldehyde),苯甲醛(benzaldehyde),丁香烯(caryophyllene),1-十七碳烯(1-heptadecene),1-十五碳烯(1-pen-tadecene)等成分。还含多种挥发性有机酸,此外,还含α,β-香树酯醇(α,β-amyrin),羽扇豆醇(lupeol),蒲公英甾醇(taraxas-terol),φ-蒲公英甾醇(φ-taraxasterol),豆甾醇(stigmasterol),谷甾醇(sitosterol)。
西医应用
1.清肠通便的作用。牛蒡的膳食纤维可以促进大肠蠕动,帮助排便,降低体内胆固醇,减少毒素、废物在体内积存,有预防和治疗便秘的功能。
2.降血压的作用。牛蒡根中所含有的牛蒡甙能使血管扩张、血压下降。
3.抗菌作用。牛蒡中含有抗菌成分,主要抗金黄色葡萄球菌,最小抑菌浓度为4000μg/ml。
4.降血糖作用。牛蒂中含有菊糖,其水提物能显著而持久地降低大鼠血糖,能增高碳水化合物耐受量。
5.利尿及泻下作用。牛蒡甙有轻度的利尿及泻下作用,能引起小鼠的轻度举尾反应。
6.抗肿瘤作用。牛蒡苦素具有抗癌作用,能抑制癌细胞中磷酸果糖基酶的活性,牛蒡甙元亦有抗癌活性。
7.治疗肾炎的作用。牛蒡甙和牛蒡酚有抗肾炎活性,能有效地治疗急性进行性肾炎和慢性肾小球肾炎。
8.促生长作用。牛蒡根制备的天然食用纤维(di-etaryfiber.DF),不同比例地加入含有中毒剂量的苋紫(ama-ranth)的基础饮食中,喂饲断奶大鼠,结果使大鼠成长加速,并超过单用基础饮食组大鼠。
9.其他作用。用二氯甲烷和乙醇,从朱蒡根中分离得抑制肿瘤生长的物质,此外,还有抗菌及抗真菌作用。
营养成分
牛蒡富含菊糖、纤维素、蛋白质、钙、磷、铁等多种维生素和矿物质,其胡萝卜素比胡萝卜高110倍,蛋白质和钙的含量为根类蔬菜之首。每100克鲜菜中含水分约87克,蛋白质4.1-4.7克,碳水化合物3.0-3.5克,脂肪0.1克,纤维素1.3-1.5克。胡萝卜素高达390毫克。维生素Cl.9毫克。在矿物质元素中含钙240毫克,磷106毫克,铁7.6毫克,并含菊糖及人体所需的多种维生素及氨基酸,它能清除体内垃圾和毒素、改善体内循环,有一定的利尿解热、抑制发炎的作用,尤其对糖尿病、肥胖症、风湿、解肝毒、便秘等有明显疗效。
牛蒡含有牛蒡甙、蛋白质、挥发油、生物碱、菊糖、VB1、VB2及人体所需的多种氨基酸,其药用和食用价值都较高。经常食用牛蒂根有促进血液循环、清除肠胃垃圾、防止人体过早衰老、润泽肌肤、防止中风和高血压、清肠排毒、降低胆固醇和血糖,并适合糖尿病患者长期食用(因牛蒡根中含有菊糖),对类风湿、抗真菌有一定疗效。
另外,牛蒡也含有一种非常特殊的物质,帮助性荷尔蒙分泌,具有强精的效果,可以增强体力,帮助脑的发育。
在牛蒡的纤维中含有一种特殊的酵素,这种酵素可以帮助肠内有益的细菌成长。有便秘的人可以多吃牛蒡,会产生意想不到的效果。
牛蒡也含有极多的铁质,具有极高的造血力,可以防止贫血是一种美容食品。
1.牛蒡根中含有丰富的膳食纤维,膳食纤维具有吸附钠的作用,并且能随粪便排出体外,使体内钠的含量降低,从而达到降血压的目的。
2.牛蒡根中钙的含量是根茎类蔬菜中最高的,钙具有将钠导入尿液并排出体外的作用,从而达到降低血压的目的。
3.牛蒡根中蛋白质的含量也极高,蛋白质可以使血管变的柔韧,能将钠从细胞中分离出来,并排出体外,也具有预防慢性高血压的作用。
4.牛蒡根中所含有的牛蒡甙能使血管扩张、血压下降。
5.牛蒡所含丰富的食物纤维为水溶性的,吸收大量的食物纤维,刺激大肠蠕动,帮助排便,有助减肥,同时降低体内胆固醇,减少毒素,废物在体内积存。
富硒藤茶精华液
富含黄酮及独特的二氢杨梅素,富含多种氨基酸和硒、钾、钙、锌等多种微量元素,富含粗蛋白质。其中,二氢杨梅素是莓茶富含的一种特殊黄酮,含量极高,世所罕见。二氢杨梅素,是藤茶的精华元素,是藤茶的主要活性成分之一。
藤茶总黄酮含量是银杏的10倍、葛根的20倍、绿茶的300倍。
富硒藤茶的奇特功效及药用价值如下:
富硒藤茶是一种在特定的地理、气候环境中生长、繁衍,属落叶藤本植物(葡萄科),富含17种氨酸和14种微量元素,并具营养性、药理性,在应用研究上前无古人。
富硒藤茶表层含有一层天然植物蛋白霜黄酮。
药用价值富硒藤茶可辅助中西药发挥更好的效果。
一、富硒藤茶属纯天然奇特植物,含人体必需的17种氨酸,14种微量元素和含量较高的功能性成份黄酮类化合物≥20%--40%,具有提高人体免疫能力的功能,特别适宜体质虚弱者及免疫力低下者。
二、富硒藤茶作为一种珍贵纯生态植物制成的保健茶。
三、
降血脂:抑制血小板聚集,降低血浆纤维蛋白原浓度,增强红细胞变形能力而起降血粘度、血脂的作用。
降血压:通过扩张大、小动脉及在根本上软化血管而起到降压作用。
降血糖:促使组织细胞强力利用血糖,活化胰脏功能,促进胰岛细胞分泌。
四:
抗血栓:溶栓、预防血栓形成。
抗肿瘤:诱导肿瘤细胞凋亡,抑制癌细胞生长,中和物质。抗衰老:捕捉自由,防止自由对脑、心肌和血管内皮细胞的氧化损伤。
五:
调节血脂:降低甘油三酯、胆固醇,升高高密度脂蛋白。降血压、降低血液粘稠度。
调节免疫:活化免疫细胞,提高抗病能力。
调节肠胃:杀灭胃肠道幽门螺旋杆菌,抑制胃肠道菌群失调。杀灭病菌,抗感染,防止胃肠炎、肝炎。
调节睡眠:失眠是大多数人的极大痛苦,由于藤茶不含咖啡因且藤茶之所以能促进睡眠,其原理在于,藤茶中的含有丰富的植物黄酮,尤其对因大脑供血供氧不足引起的失眠,通过连载细胞、活化细胞和修补细胞来改善细胞膜的通透性,使钙化萎缩的松果体活力增强、褪黑素分泌增加,提高睡眠质量。
富硒藤茶所含有的活性黄以其独特的小分子量能促进细胞吸收水分,激活细胞;增强细胞代谢功能、排除毒素;促使细胞吸取营养,改善人体的重吸收,从而达到改善细胞重生环境,延长细胞寿命。比单纯补充核酸效果好:皮肤有光泽、有弹性;
服药时能促使中西药加倍发挥药效,病症减轻快;
初饮会有苦涩的感觉,很快滋润激活舌苔味蕾回味甘甜、令人神清气爽。
六、营养眼睛提高视力
在实际应用中,人们服用富硒藤茶后,瞳孔直接光动反应效果好,夜间视力明显改善,对黑暗反应较快,眼睛暴露于亮光处,能较快恢复视敏度,改善在黑暗中视力调节功能。由于视网膜通透性改变指数降低,视网膜后硬质分泌物减少至消退,视网膜出血减少至停止,炎症消退,视觉疲劳显著减轻或消除,视力逐渐恢复正常水平。
本发明的营养液可以帮助人体清除自由基、排除体内毒素、抗氧化、能有效的抑制过氧化脂质的产生,防止血凝块,清除胆固醇,阻断肿瘤血管形成、抗癌抗衰、养护心脑血管、增强生殖功能、护肤养肤、益肝利胆、止咳祛痰平喘改善肺功能、促进组织再生和上皮组织愈合、增强免疫力等作用:
一种抗衰硒肽肽精华营养液的制备工艺,通过特定的方法合成含有丰富硒元素的复合物,并将其转化为可供使用的营养液具体步骤如下:
S1:原料准备:需要准备包括硒原料、蛋白质、矿物质、维生素和天然能量矿石在内的各种原料;
S2:蛋白质酶解处理:这一步骤涉及对蛋白质进行酶解,以便后续合成肽化蛋白硒复合物;
S3:肽化蛋白硒复合物的合成:在这一阶段,通过特定反应使蛋白质与硒原料结合,形成肽化蛋白硒复合物;
S4:能量化处理:该步骤可能涉及将某些形式的能量(如热能或光能)应用于混合物中,以促进反应的进行或改善产品的性质;
S5:络合反应:这一步是为了让肽化蛋白硒复合物与其他成分如矿物质、维生素等发生络合反应,从而增强产品的稳定性和生物利用度;
S6:强化处理:在最终的产品中增加额外的营养成分或功能性物质,以提高产品的营养价值和使用效果;
S7:稀释使用:将制成的高能复合肽化蛋白硒营养液母液按照一定比例(如6000~8000倍)加水稀释,然后用于农作物的浇灌和喷洒,以提升其富硒水平。
本发明的基本原理和主要特征和本发明的优点、本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (9)
1.一种抗衰硒肽肽精华营养液,其特征在于:包括由富硒植物、富含蛋白肽动物、特效中草药有效成分提取组成的一种抗衰硒肽肽精华液新型配方;
各组份的配比为:植物硒粉6mg、泥鳅ACE蛋白肽30mg、蛋白清肽50-60mg、阿胶肽30-50mg、沙棘果粉40-60mg、表没食子儿茶素及酸酯40mg、柠檬酸20-40mg、酵母葡聚糖50mg、山梨糖醇180mg、全脂乳粉80-100mg、牛蒡根100mg、苜蓿30-50mg、富硒藤茶精华液30mg。
2.根据权利要求1所述的一种抗衰硒肽肽精华营养液,其特征在于:所述植物栖粉为西兰花富硒蛋白粉1mg、麦苗富硒蛋白粉1mg、油菜富硒蛋白粉3mg混合而成。
3.根据权利要求1所述的一种抗衰硒肽肽精华营养液,其特征在于:所述蛋白肽为泥鳅ACE蛋白肽30mg、蛋白清肽50mg、阿胶肽30mg混合而成。
4.根据权利要求1所述的一种抗衰硒肽肽精华营养液,其特征在于:所述选用中国的苜蓿主要产自河北优质的苜蓿为原料,采用严格的生产工艺,口感鲜美,营养丰富尤其是富含蛋白质和维生素。
5.根据权利要求1所述的一种抗衰硒肽肽精华营养液,其特征在于:所述优质沙棘果粉40mg混合而成。
6.根据权利要求1所述的一种抗衰硒肽肽精华营养液,其特征在于:所述表没食子儿茶素及酸酯40mg混合而成。
7.根据权利要求1所述的一种抗衰硒肽肽精华营养液,其特征在于:所述牛蒡根100mg混合而成。
8.根据权利要求1所述的一种抗衰硒肽肽精华营养液,其特征在于:所述富硒藤茶精华液30mg混合而成。
9.根据权利要求1-8任意所述的一种抗衰硒肽肽精华营养液的制备工艺,其特征在于:通过特定的方法合成含有丰富硒元素的复合物,并将其转化为可供使用的营养液具体步骤如下:
S1:原料准备:需要准备包括原生态优质硒原料、蛋白质、矿物质、维生素等在内的各种原料;
S2:蛋白质酶解处理:这一步骤涉及对蛋白质进行酶解,以便后续合成肽化蛋白硒复合物;
S3:肽化蛋白硒复合物的合成:在这一阶段,通过特定反应使蛋白质与硒原料结合,形成肽化蛋白硒复合物;
S4:能量化处理:该步骤可能涉及将某些形式的能量(如热能或光能)应用于混合物中,以促进反应的进行或改善产品的性质;
S5:络合反应:这一步是为了让肽化蛋白硒复合物与其他成分如矿物质、维生素等发生综合反应,从而增强产品的稳定性和生物利用度;
S6:强化处理:在最终的产品中增加额外的营养成分或功能性物质,以提高产品的营养价值和使用效果;
S7:稀释使用:将制成的高能复合肽化蛋白硒营养液母液按照一定比例(如6000~8000倍)加水稀释,然后用于农作物的浇灌和喷洒,以提升其富硒水平。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410513555.XA CN119039069A (zh) | 2024-04-26 | 2024-04-26 | 一种抗衰硒肽肽精华营养液及其制备工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410513555.XA CN119039069A (zh) | 2024-04-26 | 2024-04-26 | 一种抗衰硒肽肽精华营养液及其制备工艺 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119039069A true CN119039069A (zh) | 2024-11-29 |
Family
ID=93576625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410513555.XA Pending CN119039069A (zh) | 2024-04-26 | 2024-04-26 | 一种抗衰硒肽肽精华营养液及其制备工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119039069A (zh) |
-
2024
- 2024-04-26 CN CN202410513555.XA patent/CN119039069A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101090284B1 (ko) | 홍삼과 녹용 추출물을 포함하는 드링크제 및 그의 제조방법 | |
| KR101136090B1 (ko) | 기능성 식품 및 이의 제조방법 | |
| US20090098230A1 (en) | Nutraceutical moringa composition | |
| Das et al. | Okra and its various applications in drug delivery, food technology, health care and pharmacological aspects-a review | |
| CN102511869B (zh) | 红枣生姜浓浆 | |
| KR100976816B1 (ko) | 숙취해소 및 간장과 신장기능 개선용 조성물 및 이의제조방법 | |
| Kumar et al. | Green blood therapy of wheat grass-Nature’s finest medicine’-A literature review | |
| KR101632794B1 (ko) | 흰점박이 꽃무지를 주재료로 하는 환의 제조방법 | |
| KR100977849B1 (ko) | 유산균이 함유된 김치를 포함하는 녹즙 조성물 | |
| CN106858215A (zh) | 一种百香果复合饮料 | |
| KR101999675B1 (ko) | 관상동맥성 심장질환의 예방과 치료용 생약조성물 | |
| KR101642176B1 (ko) | 성장촉진 조성물 | |
| JP3502072B2 (ja) | 肝臓保護用健康食品組成物(Healthyfoodcompositionforprotectinghepatic) | |
| Rimple et al. | Poly pharmacological effects of green blood therapy: An update | |
| CN112791175A (zh) | 提高人体新陈代谢机能和排出代谢废物的中西药组合物及其制备方法 | |
| CN111387345A (zh) | 一种复合多糖组合物及其制备方法 | |
| CN110679935A (zh) | 一种牛蒡人参精华膏及其制备方法 | |
| KR20210041387A (ko) | 갈화 추출물 및 차전자피 분말을 함유한 숙취해소용 천연차 및 그 제조방법 | |
| CN109730222A (zh) | 酵素复合液及其保健饮料 | |
| CN119039069A (zh) | 一种抗衰硒肽肽精华营养液及其制备工艺 | |
| RU2792449C2 (ru) | Состав фиточая, содержащего биологически активные добавки | |
| CN109289017A (zh) | 用于清理血管和血液的组合物及制备方法 | |
| KR101290190B1 (ko) | 오디와 검은 참깨를 포함한 건강 보조식품 조성물 및 그 제조방법 | |
| KR20090029470A (ko) | 가압전이에 의한 새콤달콤한 천년(千年)의 차 조성물과 그 제조방법 | |
| CN108967757A (zh) | 一种红枣生姜浓浆生产工艺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |